Real-life targeted next-generation sequencing for lymphoma diagnosis over 1 year from the French Lymphoma Network

Br J Haematol. 2021 Jun;193(6):1110-1122. doi: 10.1111/bjh.17395. Epub 2021 Mar 25.

Abstract

As the impact of targeted next-generation sequencing (TNGS) on daily diagnosis has not been evaluated, we performed TNGS (46 genes) on lymphomas of unclear subtype following expert haematopathological review. The potential impact on patient care and modifications of final diagnosis were divided into major and minor changes according to the European Society of Medical Oncology (ESMO) guidelines. Among 229 patients [19 primary central nervous system lymphomas (PCNSL), 48 large B-cell lymphomas (LBCLs), 89 small BCLs (SBCLs), seven Hodgkin lymphomas (HL), 66 T-cell lymphomas], the overall concordance rate of histological and TNGS diagnosis was 89·5%. TNGS confirmed the histological diagnosis in 144 cases (62·9%), changed the diagnosis in 24 cases (10·5%) and did not help to clarify diagnosis in 61 cases (26·7%). Modifications to the final diagnosis had a clinical impact on patient care in 8·3% of cases. Diagnostic modifications occurred in all types of lymphoma except in PCNSL and HL; the modification rate was 14·6% in SBCL and 12·5% in LBCL. While comparing informative and uninformative cases, no differences were found in terms of DNA amplification, quality or depth of sequencing and biopsy type. The present study highlights that TNGS may directly contribute to a more accurate diagnosis in difficult-to-diagnose lymphomas, thus improving the clinical management in routine practice.

Keywords: diagnosis; lymphoma; molecular biology; next-generation sequencing; pathology.

Publication types

  • Multicenter Study

MeSH terms

  • Aged
  • Female
  • France
  • High-Throughput Nucleotide Sequencing*
  • Humans
  • Lymphoma* / diagnosis
  • Lymphoma* / genetics
  • Male
  • Middle Aged
  • Registries*
  • Retrospective Studies